Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat.com Eli Lilly's Employer Push Could Unlock New GLP-1 DemandAuthor: Leo Miller. Article Published: 3/15/2026. 
Key Points - Eli Lilly is opening up a new way for employers to cover their weight-loss drugs.
- With half or more of employees not having coverage for obesity medications, Employer Connect could unlock significant demand for LLY.
- Meanwhile, the company's oral GLP-1 just beat out Novo's in a head-to-head type 2 diabetes duel.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
The world's most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has continued to assert its dominance in the weight-loss and diabetes drug market in 2026. The company's most recent earnings report forecast robust 25% growth for the year, well above expectations. While that would be slower than the 45% growth Lilly generated in 2025, it would still rank among the company's highest annual increases. Lilly's current GLP-1 franchises should continue to drive strong sales, but growth at sky-high rates is unlikely to be sustained indefinitely. San Francisco is the strangest city in America right now—you can hop into a self-driving car and be chauffeured by a robot, but out the window you see addicts slumped in doorways, open-air drug markets, the mentally ill screaming at the sky, and entire city blocks consumed by homeless encampments. It's ground-zero for the most disruptive technological forces of our age, and Erez lives in the Bay Area plugged into the capital, the connections, and the companies reshaping the world—the advancements in AI, blockchain, computing, and biosciences are unlike anything the world has seen before, and a tsunami of disruption is coming for everything all at once. During our most recent broadcast, we exposed what we're calling the most asymmetric opportunity of our careers: an overlooked financial company hiding a multi-billion-dollar blockchain asset Wall Street hasn't priced in—it's one of those rare situations Warren Buffett would describe as raining gold when all you have to do is step outside if you want to get rich. Watch the broadcast before the window closes now By contrast, Lilly's top competitor, Novo Nordisk A/S (NYSE: NVO), is forecasting one of its weakest revenue years in recent memory, expecting sales to decline 5% to 13% in 2026. Measured in U.S. dollars, the company hasn't seen a revenue drop of more than 5% since 2014; measured in Danish kroner, that streak stretches back to 1998. That divergence highlights Lilly's relatively stronger position, particularly in the injectable GLP-1 market currently on the market. At the same time, the healthcare company is taking steps to fortify its lead. Two key priorities are expanding access to its medicines and winning the race for an effective oral GLP-1. Employer Connect: Lilly's bid to close a large employer coverage gap One of Lilly's most significant recent moves is the launch of Employer Connect, a platform designed to address gaps in employer-sponsored obesity care. Lilly notes that roughly half of people on employer-sponsored plans lack coverage for obesity treatments. One survey found only 20% of companies with more than 200 employees cover weight-loss drugs, and just 43% of firms with 5,000 or more workers do so. That represents a substantial untapped opportunity. If employers won't provide coverage, many patients must pay out of pocket. Lilly's direct-to-consumer platform, LillyDirect, lists Zepbound at patient prices ranging roughly from $299 to $449 per month, but the drug's list price exceeds $1,000. As a result, cost is likely limiting uptake among potential users who would be covered if their employers offered benefits. Employer Connect aims to change that by offering Zepbound to employers at a discounted employer price of $449, with employees responsible for only a small share of that cost. That employer price is less than half of Zepbound's list price, which could meaningfully lower the barrier for many workers. The program also bypasses traditional pharmacy benefit managers (PBMs), which act as intermediaries between drug companies and insurers and often operate with opaque pricing. The PBM industry is highly concentrated and typically wields substantial negotiating leverage. Instead, Employer Connect lets companies choose from more than 15 independent program administrators, encouraging competition among administrators on services and value. If employers adopt Employer Connect broadly, Lilly could see a sizable lift in Zepbound sales. However, meaningful contribution to revenue may not materialize until 2027 as employers evaluate and implement the new option. If employers that already cover Zepbound switch to Employer Connect, Lilly could take a near-term pricing hit — a trade-off the company appears willing to accept given the potential for much larger patient volume. Lilly posts a win in the smaller oral type 2 diabetes market Lilly also reported encouraging data for its investigational oral GLP-1, orforglipron. In a head-to-head trial against Novo's approved oral GLP-1, oral semaglutide (marketed as Rybelsus), orforglipron produced superior reductions in blood sugar and greater weight loss among patients with type 2 diabetes. Specifically, A1C — a key blood-sugar marker — fell 2.2% with orforglipron versus 1.4% with oral semaglutide. Weight loss with orforglipron averaged 9.2% compared with 5.3% for oral semaglutide. These results support Lilly's effort to secure approval of orforglipron as an oral treatment for type 2 diabetes. Still, the oral type 2 diabetes market is small relative to the broader GLP-1 opportunity: Novo's Rybelsus generated about $3.5 billion in sales in 2025, roughly one-tenth of the combined $32.5 billion that Ozempic and Wegovy produced for Novo that year. Lilly is also pursuing approval of orforglipron as an oral obesity medication, which would address a much larger market. LLY keeps opening new doors to drive potential growth Overall, Lilly is continuing to expand potential customer bases by broadening access to current medicines and advancing new products. Although the company has already become a giant in the industry, its recent execution and ongoing innovation make it a difficult stock to count out. | 
Post a Comment
Post a Comment